In a Phase 3 Paloma-III study of Pfizer’s CDK4/6 inhibitor (Ibrance – palbociclib) and an estrogen receptor antagonist (Faslodex – fulvestrant), patients receiving the combination had significantly prolonged progression-free survival than women with breast cancer who received Faslodex, alone. Continue reading
Entinostat is currently in a Phase III trial in combination with Aromasin (exemestane – aromatase inhibitor that blocks the synthesis of estrogen) in patients with metastatic breast cancer who have recurred following treatment with an aromatase inhibitor. Continue reading
Cellular migration, a normal process in development that is lost in adulthood, is essential for cancer cells to become metastatic, thereby deadly. Continue reading
A drug that was rejected by the FDA in 2005 for the treatment of acute myeloid leukemia, and has also failed studies in pancreatic cancer will be further developed by a company called Kura, which in-licensed the drug from J&J. Continue reading
This is a timeline of the major milestones and watershed moments in cancer biology discovery and treatments. Continue reading
Researchers at the University of North Carolina have been developing a chemotherapy drug treatment utilizing iontophoresis specifically for prostate and breast cancer. Continue reading
Multikine is a new product being developed by CEL-SCi for front-line use in patients with head and neck cancer. I observed a presentation at the 2015 Biotech Showcase on January 12, 2015. A late stage clinical trial is currently enrolling – Phase III Study of LI [Multikine®] Plus SOC (Surgery + Radiotherapy or Surgery + Concurrent Radiochemotherapy) in Subjects With Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate vs. SOC Only. Continue reading
Can-Fite BioPharma announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. The study will enroll 78 patients with refractory advanced hepatocellular carcinoma with Child-Pugh Class B cirrhosis. Patients will receive 25 mg of CF102 orally twice a day; the endpoint will be overall survival between those receiving CF102 versus placebo. Continue reading
Multi-modality (surgery, chemo, radiation) therapy and combination chemotherapy (e.g, CHOP and ABVD) have long been the mainstays of treating cancer. So, we should not be surprised to read about the discovery made by scientists at Rice University and MD Anderson regarding a two-step approach involving radiation and immunotherapy. Continue reading
An experimental drug, CPI-613, was shown to be safe and induce several responses in a Phase I study of patients with advanced refractory hematologic malignancies. The drug targets mitochondrial enzymes of cancer cells and is not harmful to normal cells at therapeutic doses. Continue reading